HER2-positive Breast Cancer Clinical Trials in Guangzhou, Guangdong
6 recruitingGuangzhou, Guangdong, China
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.596 enrolled2 locationsNCT07518173
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
HER2-low Breast CancerHER2-positive Breast CancerTrastuzumab-rezetecan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University300 enrolled1 locationNCT07358182
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Not Applicable
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
HER2-positive Breast CancerDiarrhea Caused by DrugNeratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University308 enrolled1 locationNCT06892093
Recruiting
Phase 2
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled1 locationNCT06445400